Characterization of CRKL as a therapeutic target in sorafenib resistant hepatocellular carcinoma
碩士 === 國立陽明大學 === 生物藥學研究所 === 102 === Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and frequently resistant to systemic therapies and recurs even after aggressive local therapies. Currently, only sorafenib, which prolongs patient’s survival for 2-3 mon...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en_US |
| Published: |
2014
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/69356024768731054951 |